

Olaf Penack

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9515878/publications.pdf>

Version: 2024-02-01

116
papers

4,711
citations

81900

39
h-index

110387

64
g-index

117
all docs

117
docs citations

117
times ranked

5414
citing authors

#	ARTICLE	IF	CITATIONS
1	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <i>Lancet Haematology</i> , 2020, 7, e157-e167.	4.6	319
2	Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. <i>Annals of Hematology</i> , 2016, 95, 1435-1455.	1.8	169
3	Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2018, 97, 197-207.	1.8	162
4	Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. <i>Haematologica</i> , 2009, 94, 113-122.	3.5	160
5	Treatment of invasive fungal infections in cancer patientsâ€”updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2014, 93, 13-32.	1.8	143
6	Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors. <i>Blood</i> , 2010, 115, 1865-1872.	1.4	140
7	CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets. <i>Leukemia</i> , 2005, 19, 835-840.	7.2	133
8	Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2017, 96, 1775-1792.	1.8	129
9	Treatment of invasive fungal infections in cancer patientsâ€”Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2009, 88, 97-110.	1.8	128
10	NOD2 regulates hematopoietic cell function during graft-versus-host disease. <i>Journal of Experimental Medicine</i> , 2009, 206, 2101-2110.	8.5	105
11	Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. <i>Annals of Oncology</i> , 2006, 17, 1306-1312.	1.2	103
12	Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). <i>Frontiers in Immunology</i> , 2020, 11, 524.	4.8	100
13	Diagnosis of invasive fungal infections in hematology and oncologyâ€”guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). <i>Annals of Oncology</i> , 2012, 23, 823-833.	1.2	99
14	Antiviral prophylaxis in patients with solid tumours and haematological malignanciesâ€”update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2015, 94, 1441-1450.	1.8	98
15	EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. <i>Lancet Haematology</i> , 2017, 4, e414-e423.	4.6	92
16	Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). <i>Annals of Oncology</i> , 2006, 17, 1051-1059.	1.2	90
17	Danger signals activating innate immunity in graft-versus-host disease. <i>Journal of Molecular Medicine</i> , 2011, 89, 833-845.	3.9	89
18	How much has allogeneic stem cell transplantâ€”related mortality improved since the 1980s? A retrospective analysis from the EBMT. <i>Blood Advances</i> , 2020, 4, 6283-6290.	5.2	89

#	ARTICLE	IF	CITATIONS
19	Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. <i>Annals of Hematology</i> , 2014, 93, 1449-1456.	1.8	88
20	Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology. <i>Annals of Oncology</i> , 2014, 25, 936-947.	1.2	87
21	Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). <i>Annals of Hematology</i> , 2014, 93, 1083-1095.	1.8	86
22	Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1065-1077.	2.5	83
23	Inflammatory neovascularization during graft-versus-host disease is regulated by α v integrin and miR-100. <i>Blood</i> , 2013, 121, 3307-3318.	1.4	75
24	The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2011, 117, 4181-4189.	1.4	73
25	The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. <i>Experimental Hematology</i> , 2006, 34, 753-759.	0.4	70
26	EASIX and mortality after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 553-561.	2.4	70
27	Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (<sc>AGIHO</sc>). <i>Mycoses</i> , 2018, 61, 796-813.	4.0	69
28	Community acquired respiratory virus infections in cancer patientsâ€”Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology. <i>European Journal of Cancer</i> , 2016, 67, 200-212.	2.8	66
29	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 817-835.	1.2	62
30	The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2010, 120, 343-356.	8.2	62
31	Initiation of acute graft-versus-host disease by angiogenesis. <i>Blood</i> , 2017, 129, 2021-2032.	1.4	56
32	Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology. <i>Annals of Oncology</i> , 2011, 22, 1019-1029.	1.2	54
33	Central venous catheterâ€”related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2021, 100, 239-259.	1.8	54
34	Inhibition of Neovascularization to Simultaneously Ameliorate Graft-vs-Host Disease and Decrease Tumor Growth. <i>Journal of the National Cancer Institute</i> , 2010, 102, 894-908.	6.3	53
35	<i>Aspergillus galactomannan</i> testing in patients with long-term neutropenia: implications for clinical management. <i>Annals of Oncology</i> , 2008, 19, 984-989.	1.2	51
36	GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. <i>Blood</i> , 2022, , .	1.4	51

#	ARTICLE	IF	CITATIONS
37	The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. , 2022, 10, e004475.		50
38	Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 2019, 54, 662-673.	2.4	48
39	Single-Nucleotide Polymorphisms Within the Thrombomodulin Gene (<i>THBD</i>) Predict Mortality in Patients With Graft-Versus-Host Disease. Journal of Clinical Oncology, 2014, 32, 3421-3427.	1.6	42
40	Treatment of invasive fungal diseases in cancer patientsâ€”Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Mycoses, 2020, 63, 653-682.	4.0	42
41	Management of sepsis in neutropenia: guidelines of the infectious diseases working party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of Hematology, 2006, 85, 424-433.	1.8	41
42	Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantationâ€”guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of Hematology, 2012, 91, 1161-1174.	1.8	40
43	The type of ATG matters â€” Natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius. Transplant Immunology, 2007, 18, 85-87.	1.2	39
44	Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). Annals of Hematology, 2021, 100, 1603-1620.	1.8	39
45	Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel. Haematologica, 2021, 106, 446-453.	3.5	38
46	Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Annals of Hematology, 2021, 100, 321-336.	1.8	34
47	Complications after CD19+ CAR T-Cell Therapy. Cancers, 2020, 12, 3445.	3.7	32
48	Acute Graft-vs.-Host Disease-Associated Endothelial Activation in vitro Is Prevented by Defibrotide. Frontiers in Immunology, 2019, 10, 2339.	4.8	31
49	Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). Journal of Antimicrobial Chemotherapy, 2019, 74, 3315-3327.	3.0	30
50	Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia. Blood Cancer Journal, 2022, 12, 61.	6.2	30
51	Lack of Evidence That False-Positive Aspergillus Galactomannan Antigen Test Results Are Due to Treatment with Piperacillin-Tazobactam. Clinical Infectious Diseases, 2004, 39, 1401-1402.	5.8	26
52	Endothelial damage and dysfunction in acute graft-versus-host disease. Haematologica, 2021, 106, 2147-2160.	3.5	26
53	Evaluation of heated humidifiers for use on intubated patients: a comparative study of humidifying efficiency, flow resistance, and alarm functions using a lung model. Intensive Care Medicine, 2002, 28, 731-739.	8.2	25
54	Absence of P-Selectin in Recipients of Allogeneic Bone Marrow Transplantation Ameliorates Experimental Graft-versus-Host Disease. Journal of Immunology, 2010, 185, 1912-1919.	0.8	25

#	ARTICLE	IF	CITATIONS
55	Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation. <i>Blood</i> , 2009, 113, 1574-1580.	1.4	24
56	Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e46-e54.	2.0	24
57	Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia. <i>Annals of Hematology</i> , 2005, 84, 692-693.	1.8	21
58	Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. <i>Journal of Clinical Investigation</i> , 2013, 123, 2654-2662.	8.2	21
59	False-positive <i>Aspergillus</i> antigen testing due to application of piperacillin/tazobactam—is it still an issue?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 60, 117-120.	1.8	20
60	Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope—Global Registry for Emerging Fungal Infections. <i>Journal of Infection</i> , 2020, 81, 802-815.	3.3	20
61	Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 1022-1028.	2.4	19
62	Hematopoietic stem cell boost for persistent neutropenia after CAR-T-cell therapy: a GLA/DRST study. <i>Blood Advances</i> , 2023, 7, 555-559.	5.2	19
63	Single Nucleotide Polymorphisms in CD40L Predict Endothelial Complications and Mortality After Allogeneic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2018, 36, 789-800.	1.6	17
64	EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study. <i>Frontiers in Immunology</i> , 2022, 13, 877477.	4.8	17
65	Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e145-e154.	2.0	16
66	Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 426-445.	1.2	16
67	Association between low uric acid levels and acute graft-versus-host disease. <i>Annals of Hematology</i> , 2015, 94, 139-144.	1.8	14
68	Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 648-661.	2.4	14
69	Lymphangiogenesis is a feature of acute GVHD, and VEGFR-3 inhibition protects against experimental GVHD. <i>Blood</i> , 2017, 129, 1865-1875.	1.4	13
70	Acute Graft-versus-Host-Disease Other Than Typical Targets: Between Myths and Facts. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 115-124.	1.2	13
71	High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 337.e1-337.e10.	1.2	13
72	Anti-tumor effects of anti-T-cell globulin. <i>Experimental Hematology</i> , 2014, 42, 875-882.	0.4	12

#	ARTICLE	IF	CITATIONS
73	The T Cell Cytolytic Molecules Fas Ligand and TRAIL, the Trafficking Molecules CCR9, β 2 Integrin and PSGL-1, and the Immune Modulating Molecules OX40, CEACAM1, and CTLA4 Are Required for Thymic Graft-Versus-Host Disease. <i>Blood</i> , 2008, 112, 65-65.	1.4	12
74	Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome. <i>Oncotarget</i> , 2015, 6, 35095-35106.	1.8	12
75	Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 183-190.	2.4	12
76	Incidence of Acute Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation over Time: A Study from the Transplant Complications and Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2018, 132, 2120-2120.	1.4	11
77	PLZF Confers Effector Functions to Donor T Cells That Preserve Graft-versus-Tumor Effects while Attenuating GVHD. <i>Cancer Research</i> , 2013, 73, 4687-4696.	0.9	10
78	The Green Tea Catechin Epigallocatechin Gallate Ameliorates Graft-versus-Host Disease. <i>PLoS ONE</i> , 2017, 12, e0169630.	2.5	10
79	Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals. <i>International Journal of Infectious Diseases</i> , 2019, 83, 130-138.	3.3	10
80	Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT – A Prospective, Non-interventional Study of the EBMT Transplant Complications Working Party. <i>Frontiers in Immunology</i> , 2020, 11, 586.	4.8	10
81	Early bilirubinemia after allogeneic stem cell transplantation – an endothelial complication. <i>Bone Marrow Transplantation</i> , 2021, 56, 1573-1583.	2.4	10
82	Organ siderosis and hemophagocytosis during acute graft-versus-host disease. <i>Haematologica</i> , 2016, 101, e344-e346.	3.5	9
83	Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2017, 98, 160-168.	2.2	9
84	Cathepsin E Deficiency Ameliorates Graft-versus-Host Disease and Modifies Dendritic Cell Motility. <i>Frontiers in Immunology</i> , 2017, 8, 203.	4.8	9
85	The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium. <i>Bone Marrow Transplantation</i> , 2020, 55, 2270-2278.	2.4	9
86	Ocular Graft-versus-Host Disease in a Chemotherapy-Based Minor-Mismatch Mouse Model Features Corneal (Lymph-) Angiogenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6191.	4.1	7
87	Value of surveillance blood cultures in neutropenic patients – a pilot study. <i>Japanese Journal of Infectious Diseases</i> , 2005, 58, 171-3.	1.2	7
88	HEV infection in stem cell transplant recipients – retrospective study of EBMT Infectious Diseases Working Party. <i>Bone Marrow Transplantation</i> , 2022, 57, 167-175.	2.4	6
89	Anti- <i>Aspergillus</i> immunoglobulin G testing in serum of hematopoietic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2016, 18, 354-360.	1.7	5
90	Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation – a prospective, non-interventional study of the EBMT Transplant Complication Working Party. <i>Haematologica</i> , 2020, 105, 1977-1983.	3.5	5

#	ARTICLE	IF	CITATIONS
91	Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD. <i>Blood Cancer Journal</i> , 2021, 11, 42.	6.2	5
92	Cost-Benefit Assessment of Antifungal Prophylaxis with Liposomal Amphotericin B in Neutropenic Patients. <i>Oncology Research and Treatment</i> , 2007, 30, 621-626.	1.2	3
93	Ceacam1 Separates Graft-versus-Host-Disease from Graft-versus-Tumor Activity after Experimental Allogeneic Bone Marrow Transplantation. <i>PLoS ONE</i> , 2011, 6, e21611.	2.5	3
94	Steroids in neutropenic patients with sepsis – comment on How I manage haematology patients with septic shock by Jon Cohen and Stephen Drage. <i>British Journal of Haematology</i> , 2011, 155, 624-625.	2.5	3
95	Synchronous tuberculosis, Epstein-Barr virus-associated lymphoproliferative disorder and cytomegalovirus infection in an allogeneic transplant recipient: a case report. <i>SpringerPlus</i> , 2014, 3, 278.	1.2	3
96	Editorial: Endothelial Dysfunction During Inflammation and Alloimmunity. <i>Frontiers in Immunology</i> , 2018, 9, 2886.	4.8	3
97	Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. <i>Frontiers in Immunology</i> , 2020, 11, 613954.	4.8	3
98	A Novel Method to Quantify and Characterize Leukemia-Reactive Natural Killer Cells in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation following Conventional or Reduced-Dose Conditioning. <i>International Journal of Hematology</i> , 2007, 85, 326-332.	1.6	2
99	Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT. <i>Frontiers in Immunology</i> , 2020, 11, 1537.	4.8	2
100	Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 3084-3087.	2.4	2
101	Spatio-Temporal Bone Remodeling after Hematopoietic Stem Cell Transplantation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 267.	4.1	2
102	Effectiveness and safety of isavuconazole prophylaxis for invasive fungal infections in the haematologic setting. <i>Hematology</i> , 2022, 27, 723-732.	1.5	2
103	Practice patterns in chronic graft-versus-host disease patient management and patient reported outcome measures across the EBMT allogeneic transplantation network. <i>Bone Marrow Transplantation</i> , 2022, 57, 1458-1460.	2.4	2
104	Air embolism simulating atypical pneumonia. <i>British Journal of Haematology</i> , 2005, 130, 468-468.	2.5	1
105	The endothelium in graft-versus-host disease and graft-versus-leukemia. , 2013, , 479-492.		1
106	Easix Predicts Severe Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neuro-Toxicity Syndrome (ICANS) in Patients Receiving CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy. <i>Blood</i> , 2021, 138, 3861-3861.	1.4	1
107	The CAR-Hematotox Identifies Patients at High Risk for Prolonged Neutropenia, Infectious Complications and Prolonged Hospitalization Following CD19-CART in R/R LBCL. <i>Blood</i> , 2021, 138, 3852-3852.	1.4	1
108	Mast cell leukaemia. <i>British Journal of Haematology</i> , 2005, 131, 416-416.	2.5	0

#	ARTICLE	IF	CITATIONS
109	The Endothelium During Allogeneic Stem Cell Transplantation. , 2019, , 401-414.		0
110	Reduced Calcium Signaling Is Associated With Severe Graft-Versus-Host Disease: Results From Preclinical Models and From a Prospective EBMT Study. <i>Frontiers in Immunology</i> , 2020, 11, 1983.	4.8	0
111	Genetic Risk of Severe Chronic Graft-Versus-Host Disease Defined By Host-Derived CXCR3 Ligands. <i>Blood</i> , 2018, 132, 357-357.	1.4	0
112	Early Hyperbilirubinemia Is an Independent Predictor of Outcome after Allogeneic Stem Cell Transplantation and Correlates with Markers of Endothelial Cell Dysfunction. <i>Blood</i> , 2019, 134, 4487-4487.	1.4	0
113	From Ex-Vivo T-Cell Depletion to Post-Transplant Cyclophosphamide: Improved GvHD-Free & Relapse-Free Survival but Comparable Chronic GvHD Incidence in Haploidentical Transplantation. A 15 Years EBMT Registry Analysis on Behalf of the TCWP-EBMT. <i>Blood</i> , 2019, 134, 876-876.	1.4	0
114	The CXCL9 Polymorphism rs884304 Associates with Early CXCL9 Reconstitution and with Severe Chronic Graft-Versus-Host Disease (cGVHD) in Human Allograft Recipients. <i>Blood</i> , 2019, 134, 873-873.	1.4	0
115	Validating a Machine Learning Grading System for Acute Gvhd. a Study on Behalf of the EBMT Transplant Complications Working Party. <i>Blood</i> , 2021, 138, 1809-1809.	1.4	0
116	Management of Steroid-Refractory Graft-Versus-Host Disease - a Survey By the Transplant Complications Working Party of the EBMT. <i>Blood</i> , 2021, 138, 2884-2884.	1.4	0